Michael Birrer
Michael Birrer
Professor Medicine HMS
Verified email at partners.org
Title
Cited by
Cited by
Year
Integrated genomic analyses of ovarian carcinoma
Cancer Genome Atlas Research Network
Nature 474 (7353), 609, 2011
41092011
Integrated genomic characterization of endometrial carcinoma
DA Levine, Cancer Genome Atlas Research Network
Nature 497 (7447), 67-73, 2013
22612013
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
M Verheij, R Bose, XH Lin, B Yao, WD Jarvis, S Grant, MJ Birrer, E Szabo, ...
Nature 380 (6569), 75-79, 1996
20661996
Making technology our own?: domesticating technology into everyday life
M Lie, KH S°rensen
Scandinavian University Press North America, 1996
1929*1996
Incorporation of bevacizumab in the primary treatment of ovarian cancer
RA Burger, MF Brady, MA Bookman, GF Fleming, BJ Monk, H Huang, ...
New England Journal of Medicine 365 (26), 2473-2483, 2011
17292011
p53: a frequent target for genetic abnormalities in lung cancer
T Takahashi, MM Nau, I Chiba, MJ Birrer, RK Rosenberg, M Vinocour, ...
Science 246 (4929), 491-494, 1989
13631989
Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73
T Smeal, B Binetruy, DA Mercola, M Birrer, M Karin
Nature 354 (6353), 494-496, 1991
8531991
BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group
K Alsop, S Fereday, C Meldrum, A DeFazio, C Emmanuel, J George, ...
Journal of Clinical Oncology 30 (21), 2654, 2012
8062012
Dicer, Drosha, and outcomes in patients with ovarian cancer
WM Merritt, YG Lin, LY Han, AA Kamat, WA Spannuth, R Schmandt, ...
New England Journal of Medicine 359 (25), 2641-2650, 2008
7302008
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
6202018
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
L Zhang, S Volinia, T Bonome, GA Calin, J Greshock, N Yang, CG Liu, ...
Proceedings of the National Academy of Sciences 105 (19), 7004-7009, 2008
6142008
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
5672018
Finite-state language processing
E Roche, Y Schabes
MIT press, 1997
515*1997
Early events in the pathogenesis of epithelial ovarian cancer
CN Landen Jr, MJ Birrer, AK Sood
Journal of Clinical Oncology 26 (6), 995-1005, 2008
4842008
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
4612018
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
DD Bowtell, S B÷hm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ...
Nature reviews Cancer 15 (11), 668-679, 2015
4532015
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
4442017
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
JF Liu, WT Barry, M Birrer, JM Lee, RJ Buckanovich, GF Fleming, ...
The Lancet Oncology 15 (11), 1207-1214, 2014
4122014
Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.
Z Dong, MJ Birrer, RG Watts, LM Matrisian, NH Colburn
Proceedings of the National Academy of Sciences 91 (2), 609-613, 1994
4081994
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
RGW Verhaak, P Tamayo, JY Yang, D Hubbard, H Zhang, CJ Creighton, ...
The Journal of clinical investigation 123 (1), 2012
4042012
The system can't perform the operation now. Try again later.
Articles 1–20